Gilead unit’s experimental therapy shrink brain tumours by 62%
HQ Team June 2, 2025: An investigational therapy from Kite Pharma Inc., a Gilead Sciences company, has reduced tumours in 62% of the.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
HQ Team June 2, 2025: An investigational therapy from Kite Pharma Inc., a Gilead Sciences company, has reduced tumours in 62% of the.
The US regulatory body has rejected Regeneron Pharmaceuticals, Inc.,’s blood cancer drug as it did not meet the pre-approval standards of the agency.
HQ Team December 15, 2023: A new vaccine to aid the human body’s white cells to fight HIV infection may hold the key.